Literature DB >> 20491795

The Type 1 Diabetes PhysioLab Platform: a validated physiologically based mathematical model of pathogenesis in the non-obese diabetic mouse.

L Shoda1, H Kreuwel, K Gadkar, Y Zheng, C Whiting, M Atkinson, J Bluestone, D Mathis, D Young, S Ramanujan.   

Abstract

Type 1 diabetes is an autoimmune disease whose clinical onset signifies a lifelong requirement for insulin therapy and increased risk of medical complications. To increase the efficiency and confidence with which drug candidates advance to human type 1 diabetes clinical trials, we have generated and validated a mathematical model of type 1 diabetes pathophysiology in a well-characterized animal model of spontaneous type 1 diabetes, the non-obese diabetic (NOD) mouse. The model is based on an extensive survey of the public literature and input from an independent scientific advisory board. It reproduces key disease features including activation and expansion of autoreactive lymphocytes in the pancreatic lymph nodes (PLNs), islet infiltration and beta cell loss leading to hyperglycaemia. The model uses ordinary differential and algebraic equations to represent the pancreas and PLN as well as dynamic interactions of multiple cell types (e.g. dendritic cells, macrophages, CD4+ T lymphocytes, CD8+ T lymphocytes, regulatory T cells, beta cells). The simulated features of untreated pathogenesis and disease outcomes for multiple interventions compare favourably with published experimental data. Thus, a mathematical model reproducing type 1 diabetes pathophysiology in the NOD mouse, validated based on accurate reproduction of results from multiple published interventions, is available for in silico hypothesis testing. Predictive biosimulation research evaluating therapeutic strategies and underlying biological mechanisms is intended to deprioritize hypotheses that impact disease outcome weakly and focus experimental research on hypotheses likely to provide insight into the disease and its treatment.

Entities:  

Mesh:

Year:  2010        PMID: 20491795      PMCID: PMC2909407          DOI: 10.1111/j.1365-2249.2010.04166.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  122 in total

1.  Triggering of murine NK cells by CD40 and CD86 (B7-2).

Authors:  A Martín-Fontecha; E Assarsson; E Carbone; K Kärre; H G Ljunggren
Journal:  J Immunol       Date:  1999-05-15       Impact factor: 5.422

2.  Quantifying macrophage defects in type 1 diabetes.

Authors:  Athanasius F M Marée; Mitsuhiro Komba; Cheryl Dyck; Marek Łabecki; Diane T Finegood; Leah Edelstein-Keshet
Journal:  J Theor Biol       Date:  2005-01-20       Impact factor: 2.691

3.  Genetic background determines the size and structure of the endocrine pancreas.

Authors:  Troels Bock; Bente Pakkenberg; Karsten Buschard
Journal:  Diabetes       Date:  2005-01       Impact factor: 9.461

4.  Dendritic cells and macrophages are essential for the retention of lymphocytes in (peri)-insulitis of the nonobese diabetic mouse: a phagocyte depletion study.

Authors:  Tatjana Nikolic; Sacha B Geutskens; Nico van Rooijen; Hemmo A Drexhage; Pieter J M Leenen
Journal:  Lab Invest       Date:  2005-04       Impact factor: 5.662

Review 5.  The NOD mouse: a model of immune dysregulation.

Authors:  Mark S Anderson; Jeffrey A Bluestone
Journal:  Annu Rev Immunol       Date:  2005       Impact factor: 28.527

6.  NOD mice have a generalized defect in their response to transplantation tolerance induction.

Authors:  T G Markees; D V Serreze; N E Phillips; C H Sorli; E J Gordon; L D Shultz; R J Noelle; B A Woda; D L Greiner; J P Mordes; A A Rossini
Journal:  Diabetes       Date:  1999-05       Impact factor: 9.461

7.  Increased beta-cell proliferation and reduced mass before diabetes onset in the nonobese diabetic mouse.

Authors:  S Sreenan; A J Pick; M Levisetti; A C Baldwin; W Pugh; K S Polonsky
Journal:  Diabetes       Date:  1999-05       Impact factor: 9.461

Review 8.  Onset of type 1 diabetes: a dynamical instability.

Authors:  B Freiesleben De Blasio; P Bak; F Pociot; A E Karlsen; J Nerup
Journal:  Diabetes       Date:  1999-09       Impact factor: 9.461

9.  Perforin-independent beta-cell destruction by diabetogenic CD8(+) T lymphocytes in transgenic nonobese diabetic mice.

Authors:  A Amrani; J Verdaguer; B Anderson; T Utsugi; S Bou; P Santamaria
Journal:  J Clin Invest       Date:  1999-04       Impact factor: 14.808

10.  Homeostatic maintenance of natural Foxp3(+) CD25(+) CD4(+) regulatory T cells by interleukin (IL)-2 and induction of autoimmune disease by IL-2 neutralization.

Authors:  Ruka Setoguchi; Shohei Hori; Takeshi Takahashi; Shimon Sakaguchi
Journal:  J Exp Med       Date:  2005-03-07       Impact factor: 14.307

View more
  27 in total

1.  Silicon dreams of cells into symbols.

Authors:  Jeremy Gunawardena
Journal:  Nat Biotechnol       Date:  2012-09       Impact factor: 54.908

Review 2.  Mechanistic systems modeling to guide drug discovery and development.

Authors:  Brian J Schmidt; Jason A Papin; Cynthia J Musante
Journal:  Drug Discov Today       Date:  2012-09-19       Impact factor: 7.851

3.  In vitro to in vivo extrapolation and species response comparisons for drug-induced liver injury (DILI) using DILIsym™: a mechanistic, mathematical model of DILI.

Authors:  Brett A Howell; Yuching Yang; Rukmini Kumar; Jeffrey L Woodhead; Alison H Harrill; Harvey J Clewell; Melvin E Andersen; Scott Q Siler; Paul B Watkins
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-08-09       Impact factor: 2.745

Review 4.  2011 Update: antigen-specific therapy in type 1 diabetes.

Authors:  Aaron W Michels; Matthias von Herrath
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2011-08       Impact factor: 3.243

5.  Quantitative Systems Pharmacology: A Framework for Context.

Authors:  Ioannis P Androulakis
Journal:  Curr Pharmacol Rep       Date:  2016-04-08

6.  Virtual optimization of nasal insulin therapy predicts immunization frequency to be crucial for diabetes protection.

Authors:  Georgia Fousteri; Jason R Chan; Yanan Zheng; Chan Whiting; Amy Dave; Damien Bresson; Michael Croft; Matthias von Herrath
Journal:  Diabetes       Date:  2010-09-23       Impact factor: 9.461

7.  In silico model-based inference: an emerging approach for inverse problems in engineering better medicines.

Authors:  David J Klinke; Marc R Birtwistle
Journal:  Curr Opin Chem Eng       Date:  2015-11-01       Impact factor: 5.163

Review 8.  Understanding immunology via engineering design: the role of mathematical prototyping.

Authors:  David J Klinke; Qing Wang
Journal:  Comput Math Methods Med       Date:  2012-09-03       Impact factor: 2.238

9.  Tissue distribution and clonal diversity of the T and B cell repertoire in type 1 diabetes.

Authors:  Howard R Seay; Erik Yusko; Stephanie J Rothweiler; Lin Zhang; Amanda L Posgai; Martha Campbell-Thompson; Marissa Vignali; Ryan O Emerson; John S Kaddis; Dave Ko; Maki Nakayama; Mia J Smith; John C Cambier; Alberto Pugliese; Mark A Atkinson; Harlan S Robins; Todd M Brusko
Journal:  JCI Insight       Date:  2016-12-08

10.  Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis.

Authors:  Brian J Schmidt; Fergal P Casey; Thomas Paterson; Jason R Chan
Journal:  BMC Bioinformatics       Date:  2013-07-10       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.